Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCardiff Oncology Inc

Cardiff Oncology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.7953 USD 0.00 ( 0.03%)
Last update at 2026-11-06T21:00:00Z
VOLUME
345290
Market Cap
104.25M

Momentum Score

…

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.76
Low
0.80
High
52 Week Price Range
0.76
Low
3.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cardiff Oncology, Inc. is a publicly listed clinical-stage biopharmaceutical company developing targeted therapies for cancer. Major long-term growth drivers include clinical trial progress, regulatory approvals, and potential partnerships or licensing that may benefit commercialization. Investors may find the company attractive because positive clinical data could support significant upside given its focused oncology pipeline.

Key investment risks include high clinical and regulatory failure risk, likely need for additional financing and dilution, and intense competition and execution risk in oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.80
Dividend Yield
-
Revenue TTM
0.51M
Revenue Per Share
0.01
Gross Profit TTM
-34.82M
Debt / Equity
0.02
ROE
-94.09%
Net Debt
-16.64M
ROCE
-100.85%
Diluted EPS TTM
-0.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -45.88M -45.43M -41.44M -38.70M -28.29M
Net income -45.88M -45.43M -41.44M -37.51M -27.74M
Selling general administrative 14.22M 12.48M 13.04M 13.18M 11.84M
Selling and marketing expenses - - 0.40M - -
Gross profit -0.31M 0.68M 0.49M 0.39M 0.36M
Reconciled depreciation 0.90M 0.40M 0.38M 0.24M 0.45M
Ebit -45.88M -48.65M -45.41M -39.90M -28.86M
Ebitda -44.97M -48.25M -45.01M -39.67M -28.69M
Depreciation and amortization 0.90M 0.40M 0.40M 0.24M 0.17M
Non operating income net other - - - 1.20M 0.56M
Operating income -48.96M -48.65M -45.41M -39.90M -28.86M
Other operating expenses 49.55M 49.33M 45.90M 40.29M 29.21M
Interest expense - - - 1.58M 0.26M
Interest income 3.10M 3.26M 3.80M 1.58M 0.26M
Net interest income 3.10M 3.26M 3.80M 1.58M 0.26M
Income tax expense - -0.02M 0.23M -1.20M -0.55M
Total revenue 0.59M 0.68M 0.49M 0.39M 0.36M
Total operating expenses 48.65M 49.33M 45.90M 40.29M 29.21M
Cost of revenue 0.90M 0.40M 0.40M - -
Total other income expense net 3.11M 3.22M 3.97M 1.20M 0.56M
Net income from continuing ops -45.85M -45.43M -40.80M -38.70M -28.29M
Net income applicable to common shares - - - -38.73M -28.32M
Preferred stock and other adjustments - - - 0.02M 0.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 61.88M 97.19M 81.64M 116.19M 149.54M
Other current assets 1.64M 2.54M 2.30M 5.25M 4.77M
Total liab 16.50M 14.24M 11.90M 9.85M 9.13M
Total stockholder equity 45.39M 82.95M 69.74M 106.34M 140.42M
Other current liab 7.58M 7.90M 7.78M 5.18M 0.04M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.01M
Retained earnings -430.03M -384.18M -339.54M -298.10M -259.81M
Other assets - - 0.00M 1.39M 0.24M
Cash 17.47M 51.47M 21.66M 16.35M 11.94M
Total current liabilities 16.39M 13.43M 10.44M 7.81M 6.56M
Current deferred revenue - - - - 4.53M
Net debt -16.64M -49.95M -19.51M -13.63M -8.82M
Short term debt 0.73M 0.71M 0.69M 0.68M 0.55M
Short long term debt total 0.83M 1.52M 2.15M 2.71M 3.12M
Other stockholder equity 475.36M 467.09M 409.34M 404.83M 400.36M
Property plant equipment - - - 1.27M 0.38M
Total current assets 60.13M 95.05M 77.41M 111.28M 146.13M
Net tangible assets - - - 106.34M 140.42M
Short term investments 40.83M 40.28M 53.17M 88.92M 128.88M
Net receivables 0.18M 0.77M 0.29M 0.77M 0.54M
Accounts payable 8.09M 4.82M 1.97M 1.96M 1.44M
Accumulated other comprehensive income 0.05M 0.03M -0.07M -0.40M -0.14M
Common stock total equity - - - 0.00M 0.00M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - -298.10M -259.81M
Non currrent assets other 0.55M 0.07M 1.28M 1.39M 0.24M
Non current assets total 1.76M 2.14M 4.22M 4.91M 3.42M
Capital lease obligations 0.83M 1.52M 2.15M 2.71M 3.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 1.39M 13.73M 29.65M 39.04M -131.24M
Change to liabilities - - - 1.31M 0.56M
Total cashflows from investing activities 1.34M - - 38.15M -131.45M
Total cash from financing activities 2.58M 53.78M 0.00M 0.07M 35.45M
Change to operating activities - - - -1.49M -2.29M
Net income -45.85M -45.43M -41.44M -38.70M -28.29M
Change in cash -34.00M 29.82M 5.31M 4.40M -119.04M
Begin period cash flow 51.47M 21.66M 16.35M 11.94M 130.98M
End period cash flow 17.47M 51.47M 21.66M 16.35M 11.94M
Total cash from operating activities -37.92M -37.69M -30.89M -33.82M -23.04M
Issuance of capital stock 0.00M 53.41M 0.00M 14.96M 34.19M
Depreciation 0.90M 0.40M 0.40M 0.24M 0.45M
Other cashflows from investing activities -0.74M - - 0.11M 0.11M
Dividends paid - - - 0.41M 0.02M
Change to account receivables 0.59M -0.48M 0.48M -0.24M -0.21M
Sale purchase of stock - - - 0.07M 35.45M
Other cashflows from financing activities 2.58M 0.37M 36.20M 0.49M 1.29M
Change to netincome - - - 4.26M 2.95M
Capital expenditures 0.04M 0.08M 0.58M 0.89M 0.20M
Change receivables - - - -0.24M -0.21M
Cash flows other operating - - - -1.31M -0.10M
Cash and cash equivalents changes - - - 4.40M -119.04M
Change in working capital 2.18M 3.17M 6.57M -0.38M -1.79M
Stock based compensation 5.69M 4.76M 4.51M 4.26M 3.23M
Other non cash items -0.85M -0.60M -0.92M 0.77M 2.03M
Free cash flow -37.97M -37.77M -31.47M -34.71M -23.25M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CRDF
Cardiff Oncology Inc		 0.00
0.03%		 0.80 - - 205.21 3.84 133.56 -3.66
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

11055 Flintkote Avenue, San Diego, CA, United States, 92121

858 952 7570

https://www.cardiffoncology.com

30

Name Title Year Born
Dr. Mark Erlander Ph.D. CEO & Director 1960
Mr. James E. Levine Chief Financial Officer 1971
Ms. Vicki Kelemen Chief Operating Officer NA
Dr. Tod Smeal Ph.D. Chief Scientific Officer? NA
Ms. Elizabeth Anderson VP of Fin. & Admin. NA
Mr. Charles Monahan R.Ph. Sr. VP of Regulatory Affairs NA
Dr. Tod Smeal Ph.D. Chief Scientific Officer? 1965
Ms. Elizabeth Anderson VP of Finance & Administration NA
Ms. Brigitte Lindsay Senior Vice President of Finance NA
Mr. Charles Monahan R.Ph. Senior VP of Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…